May 23, 2018 / 11:37 AM / 5 months ago

BRIEF-Amneal Signs Licensing And Supply Agreement For mAbxience's Biosimilar To Roche's Avastin

May 23 (Reuters) - Amneal Pharmaceuticals Inc:

* MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES

* MABXIENCE - CO WILL LEAD PRODUCT, CLINICAL DEVELOPMENT AND SUBSEQUENT MANUFACTURE OF BEVACIZUMAB BIOSIMILAR

* MABXIENCE - UNDER AGREEMENT, AMNEAL WILL GUIDE PRODUCT THROUGH REGULATORY APPROVAL, HAVE EXCLUSIVE COMMERCIALISATION RIGHTS IN U.S. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below